

1 Ultrasound-assisted three-phase hollow fiber 2 microextraction-based method for untargeted 3 metabolomics

4 M.C. Villegas-Álvarez^a, A. Arias-Borrego^{a,b*}, I. Velasco^c, T. García-Barrera^{a*}.

5 ^aResearch Center on Health and The Environment (RENSMA), Department of Chemistry “Prof.
6 J.C. Vílchez Martín”, University of Huelva, Fuerzas Armadas Ave., 21120 Huelva, Spain.

7 ^bDepartment of Analytical Chemistry, Faculty of Chemistry, University of Sevilla, Profesor
8 García González Ave., 41012 Seville, Spain

9 ^cDepartment of Gynecology & Obstetrics, Hospital Universitari Germans Trias i Pujol, Badalona,
10 Spain.

11 Corresponding Author

12 * Prof. Tamara García Barrera

13 Research Center on Health and The Environment (RENSMA), Department of Chemistry “Prof.
14 J.C. Vílchez Martín”, University of Huelva, Fuerzas Armadas Ave., 21120 Huelva, Spain.
15 tamara@dqcm.uhu.es. ORCID: 0000-0002-8859-9550. Tel. +34 959219962

16 *Dr. Ana Arias Borrego

17 Department of Analytical Chemistry, Faculty of Chemistry, University of Sevilla, Profesor
18 García González Ave., 41012 Seville, Spain. aarias1@us.es ORCID: 0000-0002-0054-5639.
19 Tel. +34 954556442

21 ABSTRACT

22 Sample treatment for untargeted metabolomics is still the bottleneck of the analytical
23 procedure, especially for complex samples like food or biofluids. The main pitfalls are
24 the suppression of minor compounds, low metabolite coverage and the impossibility to
25 detect certain families, combined with the requirement of non-selective approaches for
26 untargeted analysis. Herein, we developed a new analytical extraction method for
27 untargeted metabolomics using a non-selective procedure based on three phase hollow
28 fiber liquid phase microextraction aided by ultrasound (**three-phase-UA-HF-LPME**)
29 followed by gas chromatography-mass spectrometry. As a proof of concept, the method
30 has been validated for **human milk** (HM). The analytical method allows extracting organic
31 nitrogenous compounds from HM, which was not possible using the conventional liquid-
32 liquid extraction (LLE) and provided cleaner chromatographic profiles and mass spectra
33 with lower background noise. Moreover, **three-phase-UA-HF-LPME** enhanced the
34 extraction of a high number of metabolites from 1.65 to 3.27-fold compared to LLE,
35 namely: fatty acids and derivatives (decanoic acid, lauric acid, palmitic acid,
36 tetradecanoic acid, palmitoleic acid, stearic acid, myristic acid, linoleic acid, azelaic acid),
37 lipids and lipid-like molecules (oleamide, monopalmitin), organic acids and derivatives
38 (lactic acid, citric acid), amino acids and peptides (glycine, proline, glutamine).
39 Otherwise, the extraction of carbohydrates and derivatives (urea, phosphoric acid,
40 galactose) decreased the fold changes from 0.15 to 0.25. Results show that our proposed
41 method is attractive owing to its limits of detection from 0.08 to 0.16 mg L⁻¹, recoveries
42 of 99-86 %, enrichment factors up to 123 and fold changes very satisfactory when
43 compared with LLE. The validation by targeted metabolomics as well as the untargeted
44 procedure showed that **three-phase-UA-HF-LPME** presents better sensitivity, enrichment
45 factors, sample throughput and metabolite coverage than the conventional LLE method

46 considered the gold-standard for untargeted metabolomics. Our results show insights into
47 the possible application of HF for untargeted metabolomics with important analytical
48 advantages in comparison with the LLE.

49

50 Keywords: Untargeted metabolomics, Hollow-fiber liquid phase microextraction,
51 ultrasound

52

53

54

55 **1. Introduction**

56

57 Untargeted metabolomics measures global sets of low-molecular-weight
58 metabolites that result from cellular activity and, therefore, they serve as a snapshot of
59 relevant biological processes [1]. These molecules usually belong to the families of amino
60 acids, lipids, organic acids, steroids, fatty acids, vitamins, and small peptides among
61 others. In contrast to proteins or genes, which require the activation of post-translational
62 modifications or epigenetics, respectively, the metabolites can serve as biomarkers of cell
63 activity, which reflect changes in the phenotype and therefore the function [2]. Metabolite
64 profiles play a critical role in diverse biological functions and they have been shown to
65 be good biomarkers for the early diagnosis and prognosis of several diseases [2–5] as well
66 as for environmental pollution monitoring using free-living organisms [6–7], to evaluate
67 the biological response against xenobiotics [8] or the food quality [9–11]. Biological
68 fluids like urine, serum or plasma are often used in metabolomics studies due to their ease
69 sampling and because they are a direct reflection of the metabolism of an individual or
70 organism [12].

71 Nevertheless, there are other less common biofluids, such as human milk (HM),
72 which can provide a valuable and complementary information, due to the potential
73 consequences for maternal–infant health [13–16]. However, the analysis of HM, is
74 complex and challenging from the analytical viewpoint, especially the sample preparation
75 since there are fats and other major components that could hide important biomarkers as
76 well as differences in concentrations and great structural diversity among metabolites.
77 Thus, cleaning the sample to remove protein interferences, as well as a subsequent
78 separation into multiple fractions to reduce sample complexity is usually required before
79 the untargeted metabolomic analysis by mass spectrometry (MS) or nuclear magnetic
80 resonance (NMR), but not other enrichment or clean-up procedures are applied to obtain
81 a wide metabolite coverage by untargeted and non-selective procedures [13,17].
82 Nevertheless, this fact can lead to signal suppression by major components, other matrix
83 effects, and interferences that difficult the detection of minor metabolites. Otherwise, it
84 has been shown that protein precipitation alone, even when solvents of different polarities
85 are used, cannot solve this problem completely [18,19]. A previous study has reported the
86 metabolic profile of HM using liquid-liquid extraction (LLE) with a chloroform-methanol
87 mixture obtaining two different phases (lower phase containing nonpolar metabolites and
88 upper phase containing polar metabolites) by NMR as the analytical platform [20,22].
89 **Subsequently**, an extraction of metabolites has been proposed using methyl tert-butyl
90 ether (MTBE) and methanol that were later centrifuged and then analyzed by mass
91 spectrometry after both, gas and liquid chromatographic separations (GC-MS, LC-MS)

92 providing a very good metabolite coverage from polar metabolites to fatty acids and lipids
93 [23]. This sample preparation analytical method has been successfully employed to
94 determine the changes in the HM metabolome during lactation [14,23,24], as well as the
95 potential impact of maternal iodine deficiency [13] and COVID-19 in the HM
96 metabolome [15,25–27].

97 The hollow fiber liquid phase microextraction (HF-LPME) is a promising
98 membrane-based analytical technique that has been successfully applied to solve many
99 analytical problems [28]. It is remarkable the reliability of the diverse HF-LPME modes
100 and the simplicity of the assembly that enables low sample consumption. This aspect is
101 particularly significant when dealing with biological samples. Furthermore, these modes
102 exhibit high enrichment factors for analytes of diverse nature, while simultaneously
103 reducing matrix effects, cross contamination, and memory effects. This is primarily
104 attributed to the disposable nature of the fiber, which eliminates the need for subsequent
105 cleaning steps and minimizes solvent usage. All these features of HF led to an
106 enhancement of the parameters of quality of the analytical method against others such as
107 LLE or solid-phase microextraction (SPME) [29,32]. Furthermore, the application of
108 ultrasound energy is a powerful aid in the acceleration of various steps in the analytical
109 process [33,34].

110 Accordingly, ultrasound-assisted (UA) extraction has been extensively used to
111 improve mass transfer between immiscible phases [35] and few research so far have used
112 ultrasound-assisted extraction combined with HF-LPME and they are related to the
113 targeted analysis trace elements in urine samples [36] and estrogens from aqueous
114 matrices [37].

115 Herein, a new analytical sample preparation method has been developed for HM
116 untargeted metabolomics. The extraction and preconcentration of the HM metabolites
117 along with fat and proteins removal were carried out in a single step by HF-LPME using
118 the three-phase mode **three-phase-HF-LPME**. Moreover, the simultaneous extraction and
119 preconcentration of HM metabolites were aided by ultrasound (**three-phase-UA-HF-**
120 **LPME**). HM metabolites were annotated by GC-MS and the figures of merit of the new
121 analytical approach were compared with the existing methods for HM metabolomics
122 regarding metabolite coverage, extraction efficiency, repeatability, sensitivity, and feature
123 detection. This sample treatment provides a handy analytical tool for the extraction of
124 features in HM metabolomics and opens further research for the pretreatment of complex
125 biological samples.

126 127 128 **2. Material and methods**

129 130 *2.1. Chemicals and reagent solutions*

131 Ultrapure water, employed for the preparation of all aqueous solutions, was
132 procured from a Milli-Q system (Millipore Milli-Q, Watford, UK). Pure standards were
133 individually dissolved in methanol (MeOH, Fisher Scientific, Nepean, Canada) to attain
134 a final concentration of 1000 mg L⁻¹ and subsequently stored at -20°C. Intermediate
135 working solutions were prepared by diluting the aforementioned solutions with methanol
136 and kept in darkness at 4°C until analysis. Sigma-Aldrich (Steinheim, Germany) was the
137 source of all standards utilized for method validation, including lactic acid, urea, glycerol,
138 proline, glutamic acid, glucose, citric acid, and serine. Additionally, O-
139 methylhydroxylamine hydrochloride, N,O-bis(trimethylsilyl)trifluoroacetamide

140 (BSTFA) + 1% trimethylchlorosilane (TCMS), as well as solvents such as pyridine
141 anhydride, n-decane, and methyl tert-butyl ether (MTBE), were also procured from
142 Sigma-Aldrich. The hollow fiber employed for the immobilization of the supported liquid
143 membrane and housing the acceptor solution was an S6/2 Accurel® polypropylene
144 hollow fiber (1800µm i.d., 450µm wall thickness, and 0.2µm pore size) purchased from
145 Membrana (Wuppertal, Germany). Acetonitrile (MeCN), utilized for the extraction, was
146 acquired from Fisher Chemical (Madrid, Spain).

147

148 2.2. Sample collection

149 Breast milk (HM) samples were collected during the first four months of infancy
150 and subsequently stored at -80 °C until analysis. The collection of HM samples took
151 place between 2019 and 2020 at the University Hospital Germans Trias I Pujol, Badalona,
152 Spain. This study received approval from the Local Ethics Committee, and written
153 informed consent was obtained from all participating women (Ethics Committee
154 Reference: PI-18-266). Comprehensive oral and written information regarding the study
155 was provided to all participants. Women with multiple gestations, diseases, or perinatal
156 complications were excluded from the study. The exclusion criteria encompassed women
157 who were unable to breastfeed due to severe symptomatology requiring intensive care
158 unit support, women who required the use of medications with potential adverse effects
159 on the infant, and those for whom obtaining HM was not feasible.

160

161 2.3. Human milk liquid-liquid extraction

162 The extraction protocol used was previously developed by Villaseñor et al. [23].
163 A total of 50 µL of HM was vortex-mixed with 175 µL of methanol (MeOH) and 175 µL
164 of MTBE (~8-fold dilution). The mixture was vortex and mixed for 1 min. Then the
165 extract was centrifuged at 4000 g for 15 min at 15 °C and then analyzed by GC-MS after
166 derivatization. The derivatization process was carried out with methoxyamine in pyridine
167 and the silylation was performed with MSTFA following a previously developed method
168 [38].

169

170 2.4. Ultrasound-assisted three-phase hollow fiber microextraction of human 171 milk metabolites

172 The extraction procedure was optimized prior to the application. The solvent bar
173 configuration of the fiber and the three-phase mode was used for **three-phase-UA-HF-**
174 **LPME** (Figure 1). The fibers were cut into 3 cm pieces and later cleaned into an
175 ultrasound bath with acetone for 5 min. The clean air-dried fiber was then sealed at one
176 end with the help of a thermal welder. Once sealed, it was immersed in n-dodecane solvent
177 for 20 seconds to facilitate the formation of the supported liquid membrane (SLM). Then,
178 the acceptor phase (50 µL of MeOH) was injected into the fiber lumen and thus, **the**
179 **analytes were extracted** from HM to n-dodecane and then to MeOH. After that, the other
180 end was sealed and introduced into the donor phase (175 µL of HM sample up to 1.4 mL
181 with Milli-Q water, ~8-fold dilution). Then, it was placed into an ultrasound bath for the
182 optimal extraction time at 5 min. Once the extraction time was elapsed, the collected
183 acceptor solutions was discharged into an Eppendorf tube and dried under a nitrogen
184 stream. **The derivatization procedure was performed in the same way as in the previous**
185 **section. Methoxyamine in pyridine was used for the initial reaction, followed by silylation**
186 **with MSTFA.**

187

188 2.5. *Mass spectrometric metabolomic analysis*

189 Extracts were analyzed by gas chromatograph (Trace GC ULTRA) equipped with
190 an ion trap analyzer model ITQ 900 (Thermo Fisher Scientific). The capillary column
191 used was a VF-5MS of dimensions: 30 m × 0.25 mm I.D. and 0.25 μm of film thickness
192 (Agilent Technologies, Tokyo, Japan). Splitless mode was selected for the injections in
193 the injector oven at 250°C and helium was used as carrier gas at 1.2 mL min⁻¹. The oven
194 temperature program started at 60 °C during 1 min, then ramped at 10 °C min⁻¹ to 325°C,
195 and cooled down during 10 min before the next injection. The electron ionization (EI)
196 source was operated at 70 eV mode. The MS detection was performed in full scan mode
197 in the m/z range 50–650 at a rate of 1 spectra/s. The total chromatographic time was 30
198 minutes. The temperature of the MS detector was kept at 280°C, using nitrogen as
199 auxiliary gas at 60 mL min L⁻¹. The acquisition, evaluation and calculation of
200 chromatographic peak areas were performed with the ChemStation software (version
201 A0903).

202

203 2.6. *Data Treatment and Metabolite Identification*

204 GC–MS raw data was processed as reported previously [11]. In brief, CDF format
205 was selected to convert the files using the Thermo File Converter tool and later, GC–MS
206 data matrix with normalized peak areas was imported into the SIMCA-P (version 11.5,
207 Umetrics). Principal component analysis (PCA) and Partial Least Squares Discriminant
208 Analysis (PLS-DA) were used to obtain predictive models to visualize the metabolic
209 information as well as to explore the differences in the number features extracted using
210 different extraction times (5, 10 and 15 min) by **three-phase-UA-HF-LPME** versus LLE.
211 Besides, the fold change values were calculated for each metabolite, in order to estimate
212 the variation in their abundance within the comparison. The quality of the model was
213 assured by the class separation (R²) and predictive (Q²) parameters. The differences
214 between the types of extraction (**three-phase-UA-HF-LPME** vs LLE) were evaluated for
215 each individual metabolite by One-way ANOVA and Tukey's test by using Statistica 8
216 (Statsoft, Tulsa, OK, USA) to find statistically significant comparisons and to investigate
217 the trend of metabolite concentrations. Then, the Benjamini-Hochberg (FDR correction)
218 method was also carried out to adjust the *p*-values. NIST Mass Spectral Library (version
219 08) was used for metabolites annotation. Those metabolites with spectrum scores > 80%
220 and concordant retention index (using the n-alkane scale) (Table S1), were used for the
221 annotation of metabolites. Target ions with higher intensities and masses were chosen
222 from each metabolite mass spectrum since they are affected by matrix into a lesser extent.
223 Moreover, we checked the area of the qualifier/target ion ratio for each metabolite and
224 those with a variation < 20% were selected. Before any statistical analysis, the internal
225 standard at 10 mg L⁻¹ (IS, Ribitol) abundance was used to normalize sample
226 concentrations to correct any instrumental variability. In addition, coefficient of signal
227 variation (CV) in quality controls (QCs) was used to filter data, considering values < 30%
228 as acceptable. Metabolites that led to the discrimination between the extraction type,
229 **THREE-PHASE-UA-HF-LPME** and LLE, were considered as statistically significant
230 using a variable importance in the projection (VIP values, a weighted sum of squares of
231 the PLS weight) ≥ 1 and *p*-values ≤ 0.05.

232

233 2.7. *Validation of the methodology by targeted metabolomics*

234 To evaluate the practical reliability of the extraction method, the figures of merit
235 were determined, namely: linearity, limit of detection (LOD), limit of quantification
236 (LOQ), repeatability (intra-day), reproducibility (inter-day), enrichment factor (Ee) and
237 recovery. For method validation, the sample phase was composed by 175 μL of HM
238 spiked with the commercial standards at different concentrations (10 mg L^{-1} of lactic and
239 glutamic acid; 25 mg L^{-1} of glucose; 50 mg L^{-1} of urea; 100 mg L^{-1} of glycerol; 5 mg L^{-1}
240 of citric acid and serine; 2.5 mg L^{-1} proline) in quintuplicate ($n=5$) to a final volume of
241 1.4 mL with ultrapure water (18.2 $\text{M}\Omega\text{ cm}$). The linearity was obtained by plotting
242 calibration curves of the relative area (analyte peak area/internal standard peak area)
243 versus the concentration of each analyte. The analytical curves were constructed at six
244 levels in triplicate, at the following concentration ranges: 2-25 $\mu\text{g mL}^{-1}$ for lactic and citric
245 acids; 30-260 $\mu\text{g mL}^{-1}$ for urea; 60-500 $\mu\text{g mL}^{-1}$ for glycerol; 0.5-7 $\mu\text{g mL}^{-1}$ for proline;
246 6-60 $\mu\text{g mL}^{-1}$ for glutamic acid; 15-150 $\mu\text{g mL}^{-1}$ for glucose and 1.5-15 $\mu\text{g mL}^{-1}$ for
247 serine. LODs and LOQs were calculated as $a + 3 S_{y/x}$ and $a + 10 S_{y/x}$, respectively, where
248 “a” is the origin ordinate and “ $S_{y/x}$ ” the random errors in the values for the slope and
249 intercept [39]. Element concentrations below LOQ were excluded from statistical
250 analysis. Repeatability and reproducibility were evaluated with the analysis of samples
251 ($n = 5$) on the same and on different days. Also, the enrichment factor (E_e) of the extraction
252 was measured with the ratio ($E_e = C_{a,f}/C_{d,i}$) where , $C_{a,f}$ is the final concentration of each
253 standard in the acceptor phase and $C_{d,i}$ is the initial concentration of each standard in the
254 sample solution. The instrumental stability was determined by multiple injections in
255 quintuplicate of a QC sample. In addition, These QC samples were injected at the
256 beginning, in the middle, and at the end of each run.

257 258 259 **3. Results and discussion**

260 261 *3.1. Optimization of the ultrasound-assisted three-phase hollow fiber microextraction of* 262 *human milk metabolites*

263 *3.1.1. Optimization of the **three-phase-UA-HF-LPME** general configuration.* Since HF-
264 LPME is the miniaturization of LLE, initially we plan to reproduce the extraction using
265 MeOH mixed with MTBE as the acceptor phase. The reason is that the previously
266 reported successful LLE method is based in a mixture of MeOH, for polar metabolites,
267 MTBE, for lipophilic metabolites and then, the diluted HM sample is mixed for a mono-
268 phasic extraction followed by the later precipitation of proteins by centrifugation [23].
269 However, the extraction of HM metabolites by HF-LPME using MeOH/MTBE in the
270 acceptor phase is not possible because the two phases (acceptor and donor) are mixed,
271 preventing the proper functioning of SLM. Therefore, the HF-LPME for HM metabolites
272 was configured in the three-phase mode using n-dodecane immobilized in the HF pores,
273 thus providing a SLM. The acceptor phase (MeOH) was filled in its lumen and the diluted
274 HM sample as the donor phase. The centrifugation step used after the traditional LLE was
275 not required in the **three-phase-UA-HF-LPME**, since unlike small molecules such as
276 metabolites, the proteins and other interfering molecules (e.g. fat components) cannot
277 cross the membrane pores. The optimization of the variables affecting HM metabolites
278 by **three-phase-UA-HF-LPME** was carried out taking into account the number of
279 metabolites later identified by GC-MS in the extracts as the main objective. Later, the
280 number of families of compounds to which these metabolites belong and the peak areas
281 of the metabolites was compared with the LLE method. Thus, several variables were

282 considered namely: acceptor phase, SLM, HM dilution factor, extraction time, fiber
283 length, ionic strength and sample pH. These variables were optimized by changing one
284 parameter at a time while utilizing standard conditions for the other ones: MeOH
285 (acceptor phase), n-dodecane (SLM), 8-fold HM dilution with Milli-Q water, 5 minutes
286 of extraction time, 3 cm of fiber length and the absence of ionic strength and pH
287 adjustment.

288 *3.1.2. Acceptor phase selection.* One of the most important parameters affecting HF-
289 LPME is the type of extracting solvent. The acceptor phase must be selective regarding
290 the nature of the analytes, which must have a high tendency to dissolve them and leave
291 the sample matrix. In addition, previous studies reported the use of different acceptor
292 phases such as MeOH or acetonitrile (MeCN) to deprotonize and to extract metabolites
293 [37,38]. Taking these considerations into account, MeOH was first selected as it is used
294 in the traditional LLE method, but MeCN was also assayed. Since MeOH provided much
295 better results in terms of the number of extracted features conserving the compound
296 families, it was selected as the acceptor phase (Figure 2a).

297 *3.1.3. Supported liquid membrane selection.* The SLM must be compatible with the fiber
298 to form a very thin organic membrane film by filling completely the pores in the fiber
299 wall. In addition, the SLM must be immiscible with the aqueous donor phase and with
300 the acceptor organic phase. Moreover, the use of a mixture of MeOH/n-dodecane solvents
301 has been previously reported as it favors the extraction of fatty acids [40,41]. Based on
302 the above considerations and in agreement with previous works [42], n-dodecane was
303 selected as the SLM.

304 *3.1.4. Driving force.* To speed up the extraction, stirring is usually selected as the driving
305 force as in most of the HF-LPME methods [18,43]. However, in order to use a minimal
306 sample volume, the magnetic stirring was ruled out for incompatibility with the
307 miniaturized model because HF was not immersed properly into the donor solution and
308 the stirrer did not rotate properly in such a low donor phase volume affecting the
309 repeatability of the **three-phase-HF-LPME**. Alternatively, an ultrasound bath was used to
310 speed up the HF-LPME process. The use of sonication usually led to short extraction
311 times, probably due to a combined process of cavitation and agitation attained inside the
312 ultrasound bath [44]. Moreover, it also made possible to work with low sample volumes
313 and higher sample throughput than using stirring. Using the new **three-phase-UA-HF-**
314 **LPME** arrangement, the other variables were optimized as follows.

315 *3.1.5. Extraction time.* The extraction efficiency was studied at 1, 5, 10, and 15 min under
316 the same conditions. As can be seen in Figure2a, the times 5 and 10 min were found to be
317 the most optimal. The extraction efficiencies were equivalent at 5 and 10 min using the
318 total number of features detected, (2411 and 2405, respectively). For this reason, 5
319 minutes was chosen to shorten the analysis time.

320 *3.1.6. Fiber length.* The extraction was carried out with different fiber lengths from 1 to
321 4 cm, and the optimum was 3 cm the since **the metabolite coverage and the total number**
322 **of features slightly better (Figure2b.)**, and no discernible influence was changed when the
323 fiber length increased from 3.5 to 4 cm. Accordingly, 3 cm was adopted as optimized fiber
324 length in the subsequent experiments.

325 *3.1.7. HM dilution factor.* The composition in HBM differs in terms of chemical structure
326 and metabolites concentration, which require often dilution of the sample and enrichment
327 before analysis. Therefore, the dilution factor is an important parameter in the extraction

328 process. Initially, we used the same dilution factor (~8-fold) as previously reported with
329 the LLE method [23]. The results obtained demonstrated good enrichment factors and
330 wide metabolite coverage detected with low sample consumption, which are explained in
331 the following sections. Therefore, it was decided to carry out the experiments under these
332 conditions.

333 *3.1.8. Ionic strength adjustment and pH adjustment.* Non-selective protocols were applied
334 to **three-phase-UA-HF-LPME** with the purpose to maximize the ability to detect the
335 higher number of metabolites and compare them with the reported extraction techniques
336 used until now in metabolomics, in which there is no prior information about the target
337 metabolites that can be extracted with a focus of untargeted analysis. Therefore, it was
338 decided not to adjust the pH and ionic strength of the sample in the future experiments,
339 like in the traditional LLE applied to untargeted metabolomics, unless a certain low
340 metabolite coverage was observed in the final application of the procedure. However, this
341 fact did not happen, as can be seen in the following section and supplementary
342 information (Figure S1).

343

344 *3.2. Comparison of LLE and **three-phase-UA-HF-LPME** for HM untargeted*
345 *metabolomics regarding metabolite coverage*

346 Figure 3 shows the main families of compounds to which the annotated
347 metabolites belong and the percentage of each class against the total number of
348 metabolites using both LLE and **three-phase-UA-HF-LPME**. As we can see, the **three-**
349 **phase-UA-HF-LPME** provides greater metabolite coverage and allows extracting a
350 greater number of metabolites (**three-phase-UA-HF-LPME** vs LLE, Table S1).
351 Interestingly, **three-phase-HF-LPME** allows the extraction of organic nitrogenous
352 compounds from HM (3% of the total number of metabolites annotated by **three-phase-**
353 **UA-HF-LPME**), which was not possible using LLE. These metabolites detected only with
354 **three-phase-UA-HF-LPME**, such as *butylamine*, may be of special interest because there
355 is scientific evidence of their possible relationship with neonatal hypergastrinemia [45].
356 On the other hand, **three-phase-UA-HF-LPME** was more efficient for the extraction of
357 fatty acids and derivatives (23% vs 7% using LLE) as well as for lipids (17% vs 14%
358 LLE). As one family of compounds (organic nitrogen compounds) cannot be extracted by
359 LLE and the total number of metabolites extracted by this analytical technique was also
360 lower, the percentages of each family of compounds referred to the latter were high as in
361 the case of non-metallic compounds (15%), carbohydrates and derivatives (29%) and
362 amino acids and peptides (14%) compared to **three-phase-UA-HF-LPME** (7%, 20% and
363 7%, respectively).

364 *3.3. Comparison of the chromatographic profiling and annotated metabolites by GC-MS*
365 *after LLE and **three-phase-UA-HF-LPME***

366 HM chromatographic profiles were obtained using both extraction methods, LLE
367 and **three-phase-UA-HF-LPME** by GC-MS analysis (Figure S1). As can be seen in SI,
368 the chromatographic profile obtained by **three-phase-UA-HF-LPME** remove background
369 noise compared to the LLE method. In order to obtain good reliability and stability of the
370 metabolomic results, the analysis was evaluated using QCs, which consisted of a pool of
371 all the samples. PCA plots displayed a good QCs clustering (Figure S2a). PLS-DA
372 showed good separation between the different extraction methods included in this study
373 and analyzed by GC-MS (Figure S2b). In addition, three pairwise comparisons between

374 LLE versus **three-phase-UA-HF-LPME** at three different times (5, 10, and 15 min) were
375 performed to identify the metabolites responsible for the discrimination between both
376 analytical techniques. The values of R^2 and Q^2 confirmed the discrimination power of the
377 models (Table S2). The efficiency of the extraction method was evaluated by the total
378 number of extracted metabolites and the total intensity of the extracted features. Figure
379 3c and 3d shown the total number of features extracted and the total number of annotated
380 metabolites with the different extraction techniques compared in this study. As can be
381 seen, LLE and **three-phase-UA-HF-LPME** allow extracting 2345 and 2411 features
382 respectively, and finally, 25 and 30 metabolites were annotated by LLE and **three-phase-**
383 **UA-HF-LPME**. Using the new **three-phase-UA-HF-LPME** method, the metabolites were
384 annotated using Kovats retention indices, tandem mass spectrometric experiments, and
385 NIST database MS searching (Table S1). Additionally, we used the fold change to explore
386 the differences in the total intensity of the m/z signal of metabolites between both
387 analytical extraction techniques (Table S3). Fold changes were computed simply as the
388 ratio between m/z peak intensity using the **three-phase-UA-HF-LPME** against the peak
389 intensity using LLE for metabolite. Thus, **the three-phase-UA-HF-LPME** technique
390 enhanced the extraction of fatty acids and derivatives such as decanoic acid (1.65-fold),
391 lauric acid (2.87-fold), tetradecanoic acid (3.05-fold), palmitic acid (3.02-fold),
392 palmitoleic acid (2.73-fold), stearic acid (2.65-fold), myristic acid (2.43-fold), linoleic
393 acid (1.54-fold), and azelaic acid (3.27). Likewise, we also found an increase of lipids
394 and lipid-like molecules such as oleamide (2.06-fold) and monopalmitin (2.75-fold),
395 organic acids and derivatives such as lactic acid (3.25-fold) and citric acid (2.67-fold),
396 amino acids and peptides such as glycine (2.01-fold), proline (2.11-fold) and glutamine
397 (3.02-fold). The extraction capability of these metabolites were significantly enhanced
398 with the **three-phase-UA-HF-LPME** method in comparison with LLE. These compounds
399 are bioactive molecules necessary for key metabolic and physiological functions related
400 with the proper development, growth and health of the newborn [46–48]. Otherwise, LLE
401 seems to be greater for the extraction of carbohydrates and derivatives such as urea (0.15-
402 fold), phosphoric acid (0.02), and galactose (0.25-fold).

403

404 3.4. Validation of the **three-phase-UA-HF-LPME** /GC-MS by targeted metabolomics

405 To evaluate the applicability of the proposed **three-phase-UA-HF-LPME**, the
406 following figures of merit were determined and compared with LLE: repeatability,
407 reproducibility, recoveries, enrichment factor, linearity and detection limits (LODs) and
408 limits of quantification (LOQs), by means of targeted metabolomics using standard
409 solutions of lactic acid, urea, glycerol, serine, proline, glutamic acid, citric acid, and
410 glucose. Ribitol was included as an internal standard to correct possible errors in the
411 signal. Linear ranges were evaluated by analyzing five different levels of concentrations
412 of standard solutions in triplicate, where the linearity coefficients were all greater than
413 99% ($R^2 > 0.99$). The recoveries were estimated by comparing the values of the samples
414 enriched in triplicate ($n=3$), obtaining recoveries within the range 86-117% [37]. The
415 LODs and LOQs were in the ranges 0.08-0.16 and 0.26-0.54 mg L^{-1} , respectively (Table
416 1). The Ee results are very high, thus enhancing the extraction efficiency of LLE. The
417 results have confirmed that the features of the method are very good and the methodology
418 that can be applied successfully for the analysis of complex samples.

419

420

4. Conclusions

421

422 The new method optimized for HM untargeted metabolomics, based on **three-**
423 **phase-UA-HF-LPME** by GC-MS provides a wide metabolite coverage with higher
424 features and family of compounds annotated than LLE, probably because the former
425 analytical technique achieves lower background noise and higher peak signal to noise
426 ratio in chromatograms and mass spectra, thus preventing the common signal
427 suppression. The analytical validation of the analytical method using commercially
428 available standards and targeted metabolomics showed lower detection limits, higher
429 enrichment factors and high fold changes in comparison with LLE. Moreover, the new
430 optimized approach allows higher sample throughput with shorter extraction times aided
431 by ultrasound and because with HF the common LLE step for proteins precipitation by
432 centrifugation is not required. Thus, HF is a potential analytical technique that can be
433 applied to untargeted metabolomics with comparable results to LLE combining both, a
434 non-selective procedure and high enrichment factors, that are ideal for untargeted analysis
435 and metabolite coverage, respectively. Our results provide insights into the possible
436 application of HF to HM untargeted metabolomics and open further research related to
437 other samples, especially complex biofluids in which the sample consumption and sample
438 throughput is critical. Further research will be focused on the analysis of the obtained
439 extract with LC-MS since it is also compatible with the polarity and volume of the
440 obtained extract using **three-phase-UA-HF-LPME** .

441

442 **Author Contributions**

443 The manuscript was written through contributions of all authors.

444

445 **Notes**

446 The authors declare no competing financial interest

447

448 **Acknowledgment**

449 This work was supported by the projects PID2021-123073NB-C21 (Spanish Ministry of
450 Science and innovation (MCIN). Generación del Conocimiento. MCIN/ AEI
451 /10.13039/501100011033/ FEDER “Una manera de hacer Europa”), PI18/01857 (Carlos
452 III Health Institut, co-funded by European Regional Development Fund “A way to
453 make Europe”), UHU-1256905 and UHU-202009 from the FEDER Andalusian
454 operative program (Ministry of Economic Transformation, Industry, Knowledge and
455 Universities, Andalusia, Spain). The authors are grateful to FEDER (European
456 Community) for financial support through grants UNHU13-1E-1611 and UNHU15-CE-
457 3140. We thank the advice of Prof. Capelo regarding the use of ultrasound for HF-LPME
458 during the 4th International Caparica Christmas Conference on Sample Treatment held in
459 Caparica (Portugal) 30th November – 3rd December 2020.

460

461 **Appendix A. Supplementary Information**

462 Supplementary data to includes detail about the material and method, results and
463 discussion sections. Two supplementary Figures and three supplementary Tables are
464 including in this file. The Supplementary data is available free of charge at <https://doi.org/>

465

466

467 **REFERENCES**

- 468 [1] G.A.N. Gowda, S. Zhang, H. Gu, V. Asiago, N. Shanaiah, D. Raftery,
469 Metabolomics-based methods for early disease diagnostics, *Expert Rev Mol*
470 *Diagn.* 8 (2008) 617–633. <https://doi.org/10.1586/14737159.8.5.617>.
- 471 [2] J.L. Spratlin, N.J. Serkova, S.G. Eckhardt, Clinical applications of metabolomics
472 in oncology: A review, *Clinical Cancer Research.* 15 (2009).
473 <https://doi.org/10.1158/1078-0432.CCR-08-1059>.
- 474 [3] P. Radfar, L. Ding, L.R. de la Fuente, H. Aboulkheyr, D. Gallego-Ortega, M.E.
475 Warkiani, Rapid metabolomic screening of cancer cells via high-throughput static
476 droplet microfluidics, *Biosens Bioelectron.* 223 (2023).
477 <https://doi.org/10.1016/j.bios.2022.114966>.
- 478 [4] P.A. LeWitt, J. Li, K.-H. Wu, M. Lu, Diagnostic metabolomic profiling of
479 Parkinson’s disease biospecimens, *Neurobiol Dis.* 177 (2023).
480 <https://doi.org/10.1016/j.nbd.2022.105962>.
- 481 [5] R. González-Domínguez, F. J. Rupérez, T. García-Barrera, C. Barbas, J. L. Gómez-
482 Ariza, Metabolomic-driven elucidation of serum disturbances associated with
483 alzheimer’s disease and mild cognitive impairment, *Curr. Alzheimer Res.* 13
484 (2016) 641–653.
- 485 [6] M.Á. García-Sevillano, T. García-Barrera, F. Navarro-Roldán, Z. Montero-
486 Lobato, J.L. Gómez-Ariza, A combination of metallomics and metabolomics
487 studies to evaluate the effects of metal interactions in mammals. Application to
488 *Mus musculus* mice under arsenic/cadmium exposure, *J Proteomics.* 104 (2014)
489 66–79. <https://doi.org/10.1016/J.JPROT.2014.02.011>.
- 490 [7] A. Arias-Borrego, M. Selma-Royo, M.C. Collado, N. Abril, T. García-Barrera,
491 Impact of “chemical cocktails” exposure in shaping mice gut microbiota and the
492 role of selenium supplementation combining metallomics, metabolomics, and
493 metataxonomics, *J Hazard Mater.* 438 (2022).
494 <https://doi.org/10.1016/j.jhazmat.2022.129444>.
- 495 [8] M. A. García-Sevillano, T. García-Barrera, N. Abril, C. Pueyo, J. López-Barea, J.
496 L. Gómez-Ariza, Omics technologies and their applications to evaluate metal
497 toxicity in mice *M. spretus* as a bioindicator, *J Proteomics* 104 (2014) 42–3. <https://doi.org/10.1016/j.jprot.2014.02.032>.
- 499 [9] M.J. Primitivo, M. Neves, C.L. Pires, P.F. Cruz, C. Brito, A.C. Rodrigues,
500 C.C.C.R. de Carvalho, M.M. Mortimer, M.J. Moreno, R.M.M. Brito, D.C. Vaz,
501 V.S. Ribeiro, Edible flowers of *Helichrysum italicum*: Composition, nutritive
502 value, and bioactivities, *Food Research International.* 157 (2022).
503 <https://doi.org/10.1016/j.foodres.2022.111399>.
- 504 [10] M.A. Farag, F. Elmetwally, R. Elghanam, N. Kamal, K. Hellal, H.S. Hamezah, C.
505 Zhao, A. Mediani, Metabolomics in tea products; a compile of applications for
506 enhancing agricultural traits and quality control analysis of *Camellia sinensis*,
507 *Food Chem.* 404 (2023). <https://doi.org/10.1016/j.foodchem.2022.134628>.

- 508 [11] R. Sun, R. Xing, J. Zhang, T. Deng, Y. Ge, W. Zhang, Y. Chen, Quality changes
509 of HHP orange juice during storage: Metabolomic data integration analyses, *Food*
510 *Chem.* 404 (2023). <https://doi.org/10.1016/j.foodchem.2022.134612>.
- 511 [12] A.D. Maher, S.F.M. Zirah, E. Holmes, J.K. Nicholson, Experimental and analytical
512 variation in human urine in ¹H NMR spectroscopy-based metabolic phenotyping
513 studies, *Anal Chem.* 79 (2007) 5204–5211. <https://doi.org/10.1021/ac070212f>.
- 514 [13] A. Arias-Borrego, I. Velasco, J.L. Gómez-Ariza, T. García-Barrera, Iodine
515 deficiency disturbs the metabolic profile and elemental composition of human
516 breast milk, *Food Chem.* 371 (2022).
517 <https://doi.org/10.1016/j.foodchem.2021.131329>.
- 518 [14] K.L. Olshan, A.R. Zomorodi, M. Pujolassos, J. Troisi, N. Khan, B. Fanelli, V.
519 Kenyon, A. Fasano, M.M. Leonard, Microbiota and metabolomic patterns in the
520 breast milk of subjects with celiac disease on a gluten-free diet, *Nutrients.* 13
521 (2021). <https://doi.org/10.3390/nu13072243>.
- 522 [15] M. Wójcik, H. Mojska, Human milk metabolome: Impact of gestational age,
523 lactational stage and maternal diet, *Rocz Panstw Zakl Hig.* 73 (2022) 139–145.
524 <https://doi.org/10.32394/rpzh.2022.0214>.
- 525 [16] A. Arias-Borrego, F.J. Soto Cruz, M. Selma-Royo, C. Bäuerl, E. García Verdevio,
526 F.J. Pérez-Cano, C. Lerin, I. Velasco López, C. Martínez-Costa, M.C. Collado,
527 M.C. Collado, T. García-Barrera, Metallomic and Untargeted Metabolomic
528 Signatures of Human Milk from SARS-CoV-2 Positive Mothers, *Mol Nutr Food*
529 *Res.* 66 (2022). <https://doi.org/10.1002/mnfr.202200071>.
- 530 [17] L.S. Nolan, A.N. Lewis, Q. Gong, J.J. Sollome, O.N. Dewitt, R.D. Williams, M.
531 Good, Untargeted metabolomic analysis of human milk from mothers of preterm
532 infants, *Nutrients.* 13 (2021). <https://doi.org/10.3390/nu13103604>.
- 533 [18] M.C. Villegas-Álvarez, B. Callejón-Leblic, G. Rodríguez-Moro, J.L. Gómez-
534 Ariza, A. Arias-Borrego, T. García-Barrera, Optimization of hollow-fiber liquid
535 phase microextraction for polychlorinated biphenyls in human breast milk, *J*
536 *Chromatogr A.* 1626 (2020). <https://doi.org/10.1016/j.chroma.2020.461381>.
- 537 [19] Y. Yang, C. Cruickshank, M. Armstrong, S. Mahaffey, R. Reisdorph, N.
538 Reisdorph, New sample preparation approach for mass spectrometry-based
539 profiling of plasma results in improved coverage of metabolome, *J Chromatogr A.*
540 1300 (2013) 217–226. <https://doi.org/10.1016/j.chroma.2013.04.030>.
- 541 [20] E.J. Want, G. O’Maille, C.A. Smith, T.R. Brandon, W. Uritboonthai, C. Qin, S.A.
542 Trauger, G. Siuzdak, Solvent-dependent metabolite distribution, clustering, and
543 protein extraction for serum profiling with mass spectrometry, *Anal Chem.* 78
544 (2006) 743–752. <https://doi.org/10.1021/ac051312t>.
- 545 [21] F.C. Marincola, A. Noto, P. Caboni, A. Reali, L. Barberini, M. Lussu, F. Murgia,
546 M.L. Santoru, L. Atzori, V. Fanos, A metabolomic study of preterm human and
547 formula milk by high resolution NMR and GC/MS analysis: Preliminary results,

- 548 Journal of Maternal-Fetal and Neonatal Medicine. 25 (2012) 62–67.
549 <https://doi.org/10.3109/14767058.2012.715436>.
- 550 [22] G. Praticò, G. Capuani, A. Tomassini, M.E. Baldassarre, M. Delfini, A. Miccheli,
551 Exploring human breast milk composition by NMR-based metabolomics, *Nat Prod*
552 *Res.* 28 (2014) 95–101. <https://doi.org/10.1080/14786419.2013.843180>.
- 553 [23] A. Villaseñor, I. Garcia-Perez, A. Garcia, J.M. Posma, M. Fernández-López, A.J.
554 Nicholas, N. Modi, E. Holmes, C. Barbas, Breast milk metabolome
555 characterization in a single-phase extraction, multiplatform analytical approach,
556 *Anal Chem.* 86 (2014) 8245–8252. <https://doi.org/10.1021/ac501853d>.
- 557 [24] N.J. Andreas, M.J. Hyde, M. Gomez-Romero, M.A. Lopez-Gonzalvez, A.
558 Villaseñor, A. Wijeyesekera, C. Barbas, N. Modi, E. Holmes, I. Garcia-Perez,
559 Multiplatform characterization of dynamic changes in breast milk during lactation,
560 *Electrophoresis.* 36 (2015) 2269–2285. <https://doi.org/10.1002/elps.201500011>.
- 561 [25] K. Li, J. Jiang, H. Xiao, K. Wu, C. Qi, J. Sun, D. Li, Changes in the metabolite
562 profile of breast milk over lactation stages and their relationship with dietary intake
563 in Chinese women: HPLC-QTOFMS based metabolomic analysis, *Food Funct.* 9
564 (2018) 5189–5197. <https://doi.org/10.1039/c8fo01005f>.
- 565 [26] Y.-C. Zhao, Y. Zhang, C.-X. Liu, D.-Y. Yan, P. Dong, Compositional Differences
566 between Preterm Milk of Different Gestational Ages with the Term Milk: A
567 Comparative Lipidomic Study by LC-MS/MS, *European Journal of Lipid Science*
568 *and Technology.* 124 (2022). <https://doi.org/10.1002/ejlt.202100224>.
- 569 [27] E. Sakarya, N.T. Sanlier, N. Sanlier, The relationship between human milk, a
570 functional nutrient, and microbiota, *Crit Rev Food Sci Nutr.* (2021).
571 <https://doi.org/10.1080/10408398.2021.2008301>.
- 572 [28] G. Boudry, E. Charton, I. Le Huerou-Luron, S. Ferret-Bernard, S. Le Gall, S. Even,
573 S. Blat, The Relationship Between Breast Milk Components and the Infant Gut
574 Microbiota, *Front Nutr.* 8 (2021). <https://doi.org/10.3389/fnut.2021.629740>.
- 575 [29] M. Alexovic, B. Horstkotte, P. Solich, J. Sabo, Automation of static and dynamic
576 non-dispersive liquid phase microextraction. Part 2: Approaches based on
577 impregnated membranes and porous supports, *Anal. Chim. Acta* 907 (2016) 18–
578 30. <http://dx.doi.org/10.1016/j.aca.2015.11.046>.
- 579 [30] L.M. Madikizela, V.E. Pakade, S. Ncube, H. Tutu, L. Chimuka, Application of
580 hollow fibre-liquid phase microextraction technique for isolation and pre-
581 concentration of pharmaceuticals in water, *Membranes (Basel).* 10 (2020) 1–25.
582 <https://doi.org/10.3390/membranes10110311>.
- 583 [31] S. Pedersen-Bjergaard, K.E. Rasmussen, J.A. Jönsson, Liquid-Phase
584 Microextraction (LPME) Utilizing Porous Hollow Fibers, 2011.
585 <https://doi.org/10.1002/9780813823621.ch7>.
- 586 [32] A. Domínguez-Tello, A. Arias-Borrego, T. García-Barrera, J.L. Gómez-Ariza,
587 Application of hollow fiber liquid phase microextraction for simultaneous
588 determination of regulated and emerging iodinated trihalomethanes in drinking

- 589 water, J. Chromatography A 1402 (2015) 8–16.
590 <https://doi.org/10.1016/j.chroma.2015.05.020>
- 591 [33] M.D.L. de C. F. Priego Capote, Analytical Applications of Ultrasound, 1st ed.,
592 Elsevier, 2006.
- 593 [34] J. Regueiro, M. Llompert, C. Garcia-Jares, J.C. Garcia-Monteagudo, R. Cela,
594 Ultrasound-assisted emulsification-microextraction of emergent contaminants and
595 pesticides in environmental waters, J Chromatogr A. 1190 (2008) 27–38.
596 <https://doi.org/10.1016/j.chroma.2008.02.091>.
- 597 [35] N.A. Tsochatzidis, P. Guiraud, A.M. Wilhelm, H. Delmas, Determination of
598 velocity, size and concentration of ultrasonic cavitation bubbles by the phase-
599 Doppler technique, Chem Eng Sci. 56 (2001) 1831–1840.
600 [https://doi.org/10.1016/S0009-2509\(00\)00460-7](https://doi.org/10.1016/S0009-2509(00)00460-7).
- 601 [36] K.-C. Hsu, C.-F. Lee, Y.-Y. Chao, C.-C. Hung, P.-C. Chen, C.-H. Chiang, Y.-L.
602 Huang, Ultrasound-assisted hollow fiber/ionic liquid-based liquid phase
603 microextraction using an ionic liquid solvent for preconcentration of cobalt and
604 nickel ions in urine samples prior to FAAS determination, J Anal At Spectrom. 31
605 (2016) 2338–2345. <https://doi.org/10.1039/c6ja00183a>.
- 606 [37] S.X.L. Goh, H.K. Lee, An alternative perspective of hollow fiber-mediated
607 extraction: Bundled hollow fiber array-liquid-phase microextraction with
608 sonication-assisted desorption and liquid chromatography–tandem mass
609 spectrometry for determination of estrogens in aqueous matrix, J Chromatogr A.
610 1488 (2017) 26–36. <https://doi.org/10.1016/j.chroma.2017.01.081>.
- 611 [38] P. Begley, S. Francis-McIntyre, W.B. Dunn, D.I. Broadhurst, A. Halsall, A. Tseng,
612 J. Knowles, R. Goodacre, D.B. Kell, Development and performance of a gas
613 chromatography-time-of-flight mass spectrometry analysis for large-scale
614 nontargeted metabolomic studies of human serum, Anal Chem. 81 (2009) 7038–
615 7046. <https://doi.org/10.1021/ac9011599>.
- 616 [39] James Miller, Jane C Miller, Statistics and Chemometrics for Analytical
617 Chemistry, 2011.
618 https://books.google.es/books/about/Statistics_and_Chemometrics_for_Analytic.html?id=8FtTDwAAQBAJ&redir_esc=y (accessed February 17, 2023).
- 620 [40] A. Bourdin-Pintueles, L. Galineau, L. Nadal-Desbarats, C. Dupuy, S. Bodard, J.
621 Busson, A. Lefèvre, P. Emond, S. Mavel, Maternal Rat Metabolomics: Amniotic
622 Fluid and Placental Metabolic Profiling Workflows, J Proteome Res. 20 (2021)
623 3853–3864. <https://doi.org/10.1021/acs.jproteome.1c00145>.
- 624 [41] A. Baesu, C. Audet, S. Bayen, Evaluation of different extractions for the metabolite
625 identification of malachite green in brook trout and shrimp, Food Chem. 369
626 (2022). <https://doi.org/10.1016/j.foodchem.2021.130567>.
- 627 [42] T. Seidensticker, A.J. Vorholt, A. Behr, The mission of addition and fission -
628 catalytic functionalization of oleochemicals, European Journal of Lipid Science
629 and Technology. 118 (2016) 3–25. <https://doi.org/10.1002/ejlt.201500190>.

- 630 [43] M. Teramoto, H. Matsuyama, N. Ohnishi, S. Uwagawa, K. Nakai, Extraction of
631 Ethyl and Methyl Esters of Polyunsaturated Fatty Acids with Aqueous Silver
632 Nitrate Solutions, *Ind Eng Chem Res.* 33 (1994) 341–345.
633 <https://doi.org/10.1021/ie00026a026>.
- 634 [44] A. Gjelstad, Three-phase hollow fiber liquid-phase microextraction and parallel
635 artificial liquid membrane extraction, *TrAC - Trends in Analytical Chemistry.* 113
636 (2019) 25–31. <https://doi.org/10.1016/j.trac.2019.01.007>.
- 637 [45] M.A. Bello-López, M. Ramos-Payán, J.A. Ocaña-González, R. Fernández-Torres,
638 M. Callejón-Mochón, Analytical Applications of Hollow Fiber Liquid Phase
639 Microextraction (HF-LPME): A Review, *Anal Lett.* 45 (2012) 804–830.
640 <https://doi.org/10.1080/00032719.2012.655676>.
- 641 [46] N.A. Tsochatzidis, P. Guiraud, A.M. Wilhelm, H. Delmas, Determination of
642 velocity, size and concentration of ultrasonic cavitation bubbles by the phase-
643 Doppler technique, *Chem Eng Sci.* 56 (2001) 1831–1840.
644 [https://doi.org/10.1016/S0009-2509\(00\)00460-7](https://doi.org/10.1016/S0009-2509(00)00460-7).
- 645 [47] L.M. Lichtenberger, J.W. Gardner, J.C. Barreto, F.H. Morriss, Evidence for a role
646 of volatile amines in the development of neonatal hypergastrinemia, *J Pediatr*
647 *Gastroenterol Nutr.* 13 (1991) 342–346. [https://doi.org/10.1097/00005176-](https://doi.org/10.1097/00005176-199111000-00002)
648 [199111000-00002](https://doi.org/10.1097/00005176-199111000-00002).
- 649 [48] D. Garwolińska, J. Namieśnik, A. Kot-Wasik, W. Hewelt-Belka, Chemistry of
650 Human Breast Milk - A Comprehensive Review of the Composition and Role of
651 Milk Metabolites in Child Development, *J Agric Food Chem.* 66 (2018) 11881–
652 11896. <https://doi.org/10.1021/acs.jafc.8b04031>.

653

654 **Figures**

655 Figure 1. Schematic drawing of the **three-phase-UA-HF-LPME** process used for the
656 extraction

657 Figure 2. Total number of molecular features extracted by three-phase-UA-HF-LPME
658 and later annotated by GC-MS depending; a) effect of solvents as acceptor phase (MeOH
659 or MeCN) and extraction times, b) **effect of fiber length on the extraction efficiency at**
660 **different extraction times (gray line=5min, red line=10min and blue line=15 min).**

661 Figure 3. Metabolite coverage according to the families of compounds using both a) LLE
662 and b) **three-phase-UA-HF-LPME** for human milk metabolomics. Venn diagram
663 comparing c) total number extracted features and d) total number annotated metabolites
664 using **three-phase-UA-HF-LPME** and LLE by GC-MS.

665

666 **Table 1.** Validation parameters of the proposed method in comparison with LLE.

| Validation parameters | Lactic acid | Glutamic acid | Urea | Glycerol | Glucose | Citric acid | Serine | Proline |
|--|--------------|---------------|--------------|--------------|--------------|--------------|--------------|--------------|
| LLE (*) | | | | | | | | |
| LOD mg L ⁻¹ * | 0.53 | 1.51 | 3.22 | 4.63 | 0.53 | 0.20 | 0.70 | 0.13 |
| LOQ mg L ⁻¹ * | 1.87 | 5.03 | 10.72 | 15.44 | 1.60 | 0.61 | 2.32 | 0.64 |
| Intra-day (%RSD) n=5 * | 3.5 | 3 | 4.1 | 4 | 4.7 | 5.8 | 3.9 | 6.8 |
| Inter-day (%RSD) n=5 * | 5.0 | 6.6 | 4.7 | 5.2 | 6.7 | 7.8 | 4.7 | 10.8 |
| Recovery (%) n=3 | 97.5 | 95.6 | 100.5 | 98.4 | 90.1 | 80.3 | 103.2 | 82.4 |
| Average concentration (mg L ⁻¹ ± S.E.M) | 12.4± 0.5 | 98.3±3.2 | 160.4±8.9 | 420.3±26.4 | 99.3±7.5 | 70.9±5.7 | 6.8±4.5 | 2.2±0.7 |
| three-phase-UA-HF-LPME | | | | | | | | |
| LOD (mg L ⁻¹) | 0.16 | 0.08 | 0.08 | 0.16 | 0.14 | 0.09 | 0.14 | 0.09 |
| LOQ (mg L ⁻¹) | 0.54 | 0.26 | 0.27 | 0.53 | 0.48 | 0.53 | 0.46 | 0.48 |
| Intra-day (%RSD) n=5 | 0.24 | 10.46 | 6.74 | 3.64 | 6.93 | 4.37 | 2.42 | 7.96 |
| Inter-day (%RSD) n=5 | 6.31 | 8.09 | 3.71 | 5.20 | 4.93 | 8.94 | 5.99 | 6.11 |
| Recovery (%) n=3 | 86.4 | 99.2 | 98.1 | 90.6 | 98.2 | 98.5 | 97.8 | 98.4 |
| Ee (RSD%) n=3 | 15 (12) | 123 (5) | 8 (7) | 107 (10) | 75 (4) | 84 (6) | 103 (11) | 78.9 (16) |
| <i>Linearity</i> | | | | | | | | |
| Regression equation | Y=0.79X+1.75 | Y=0.06X+2.48 | Y=0.08X+1.48 | Y=0.12X-4.74 | Y=0.03X+2.27 | Y=0.03X+0.29 | Y=0.34X+3.21 | Y=0.25X+0.98 |
| Determination coefficient (R ²) | 0.998 | 0.996 | 0.997 | 0.991 | 0.993 | 0.991 | 0.994 | 0.997 |
| Range (mg L ⁻¹) | 0.54-23 | 0.26-60 | 0.27-260 | 0.53-500 | 0.48-125 | 0.53-25 | 0.46-15 | 0.48-7 |
| Average concentration | 15.3± 0.9 | 120.6±1.3 | 149.4±6.2 | 450.4±29.6 | 104.3±4.7 | 85.2±1.2 | 5.6±0.6 | 3.1±0.4 |

mg L⁻¹ ± S.E.M)

667

668

669

Enrichment factors, Ee ; S.E.M, standard error of the mean; (*)Validation parameters in LLE according to literature [21].

670